It is well-documented that Hpx plays a neuroprotective role after ischemic injury; therefore, it should be evaluated as a dynamic therapeutic target, specifically in patients with SCD [20,21,22,23]. The gene discussed is HPX; the disease is Schnyder corneal dystrophy.